Next Article in Journal
Characteristics of Fungal Communities in Lava Plateau Ecosystems
Next Article in Special Issue
Saccharomyces boulardii CNCM I-745 Stimulates Intracellular Antimicrobial Activity Against Salmonella Typhimurium in Murine Macrophages
Previous Article in Journal
Urbanization-Induced Shifts in Microbial Functional Genes of Wetland Nitrogen Cycling Promote Nitrous Oxide (N2O) Emissions
Previous Article in Special Issue
Prolactin and 17β-Estradiol Are Epigenetic Regulators That Modify the Effector Response of Bovine Macrophages During Staphylococcus aureus Challenge
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Microorganisms
Volume 14
Issue 3
10.3390/microorganisms14030641
microorganisms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Periodontal Disease and Its Association with Porphyromonas gingivalis: Current Understanding of Microbial Dysbiosis, Immunopathology and Immune Evasion

by
Samantha Robins
1,
Alex Strachan
2,
Vehid Salih
3 and
Andrew Foey
1,*
1
School of Biomedical Sciences, University of Plymouth, Plymouth PL4 8AA, UK
2
Plymouth Electron Microscopy Centre, University of Plymouth, Plymouth PL6 8BT, UK
3
Peninsula Dental School, University of Plymouth, Plymouth PL4 8AA, UK
*
Author to whom correspondence should be addressed.
Microorganisms 2026, 14(3), 641; https://doi.org/10.3390/microorganisms14030641
Submission received: 22 January 2026 / Revised: 24 February 2026 / Accepted: 3 March 2026 / Published: 12 March 2026
(This article belongs to the Special Issue Microbial Infections and Host Immunity)
Browse Figure
Versions Notes

Abstract

Porphyromonas gingivalis is described as a keystone pathogen associated with periodontal disease (PD), which exhibits enhanced representation upon microbial dysbiosis in such a chronic inflammatory disease. This oral pathogen drives and contributes to a dysregulated immune response, resulting in stages of aggressive destructive immune activation and inflammation punctuated by immune suppression, which underlies the relapsing–remitting nature of this disease. The understanding of key mechanisms and balance between protective innate, adaptive immune responses and dysregulated responses, linked to changes in the oral mucosal microbial environment, will afford researchers the potential to manipulate oral mucosal environments for clinical benefit. This review focuses on the dynamic interactions between the oral pathogen P. gingivalis and the immune system with an emphasis on immune evasion and how the potential correction of these mechanisms may benefit future therapeutic interventions, leading to the successful treatment of PD.

1. Introduction to Periodontal Disease

The human oral cavity accommodates approximately 700 species of bacteria. Together, these communities comprise the oral microbiome [1], a rich and diverse blend of microorganisms adhering to the surfaces of teeth, as well as one another, and located within the gingival sulcus as biofilms. Any change, or dysbiosis, in this community and interaction of the bacteria between themselves and/or the oral tissues can lead to oral and, specifically, periodontal disease (PD). PD has been estimated to affect up to 50% of the global population, and it is considered one of the most prevalent chronic conditions with over 1 billion people impacted by the disease [2]. Affecting mainly adults, it is one of the most prominent diseases, particularly among older adults [3]. PDs comprise a range of inflammatory conditions affecting the supporting structures of the teeth, i.e., the gingiva, periodontal ligament and alveolar bone, and include gingivitis (reversible) and periodontitis (non-reversible). Gingivitis is the reversible stage of disease as a result of excessive plaque and features erythematous bleeding and swollen gingiva, which can be managed effectively with improved oral hygiene care. However, PD is irreversible, due to the painful infection and permanent destruction of underlying periodontal tissues, especially of the periodontal ligament attachments to the alveolar bone, as well as gingival tissue, and often requires surgical intervention. PD causes gingiva to recede, exposing the collagenous tissues that connect the soft tissue (gingiva, periodontal ligament) to the hard tissues of the cementum and bone, creating deeper pockets in the gingival sulcus and allowing microbial products and enzymes to erode the healthy bone beneath. This progressive destruction of both soft and hard tissues is meditated by a complex array of interchange between the dysbiosis of the microbial community and the aberrant immune responses within the tissues [4]. In 2017, a periodontal classification jointly defined by the American Association of Periodontology and European Federation of Periodontology defined periodontitis as a chronic and multifactorial inflammatory disease leading to clinical attachment loss, the pocketing of the sulcus and gingival bleeding as characteristic signs. The new classification describes the new multi-dimensional severity and complexity of the disease and how to grade it [5]. PD can be graded depending on the rate of progression, responsiveness to standard therapy and its impact on systemic health. The clinical attachment loss (CAL) of tissues may be considered as slow, moderate or rapid after 5 years of diagnosis.
Putative periodontal pathogens are enhanced in dysbiosis, yet good oral hygiene and care, alongside the therapeutic removal of the advanced biofilm (plaque), can ameliorate inflammation. It is important to acknowledge that the severity of the disease depends on environmental and host risk factors, both modifiable (e.g., smoking) and non-modifiable (e.g., genetic susceptibility). Continued tissue destruction induces a continuous positive feedback loop of proteolysis, inflammation, and beneficial conditions for periodontal pathogens. Keystone microbial pathogens and sustained gingival inflammation are critical to periodontal disease progression. One such keystone bacterium has been identified, and considerable research has shown that Porphyromonas gingivalis (P. gingivalis), a Gram-negative anaerobic bacterium, is the major etiologic agent which contributes to chronic periodontitis [6]. Furthermore, the impact of chronic inflammatory diseases at sites distal to the oral cavity on periodontitis, and the defined role of periodontitis in systemic inflammation, is also becoming recognized in PD pathogenesis [7].

2. The Oral Microbiota in Health and Periodontal Disease

The oral microbiota plays a prominent role in dictating the health of the oral mucosa and teeth, effectively controlling immune activation or tolerance. The healthy oral microbiota is predominated by bacterial populations consisting of Gram-positive aerobic bacteria such as Streptococcus sanguinis, Streptococcus oralis, Actinomyces naesludii and specific genera including Veillonella spp., Neisseria, Rothia, Corynebacterium and Actinomyces, with an appreciable scarcity of spirochetes and motile bacilli [8]. With inflammatory progression to gingivitis, the microbiota changes, with up to half the population being represented by Gram-positive cocci and a slight increase in spirochetes and motile bacteria, with an accumulation of Prevotella intermedia, Veillonela spp. and the scaffold bacterium Fusobacteria nucleatum, to which these later colonizing pathogenic bacteria adhere. The progression of early gingivitis to longer-term destructive periodontitis results in the dysbiosis of the oral microbiome in favour of Gram-negative obligate anaerobes predominated by motile rods and spirochetes, where the genera Eubacterium, Campylobacter, Treponema and Tannerella are associated with chronic PD and a strong correlation between dysbiosis and pocket depth with Porphyromonas, Treponema, and Tannarella over Rothia and Corynebacterium [8]. This dysbiotic periodontitis-associated microbiome contains orange complex bacteria F. nucleatum and Prevotella intermedia [9]; the green complex Aggregatibacter actinomycemcomitans; and red complex bacteria Tanerella forsythia, Treponema denticola and Porphyromonas gingivalis [10,11,12,13]. In addition, acute periodontitis is associated with increased colonization by both A. actinomycemcomitans and P. gingivalis [14,15], whereas the red complex bacteria are strongly associated with advanced periodontitis. Such changes in microbial populations and their aggregation in biofilms, such as plaque, will impact the availability and recognition of the microbial virulence factors utilized in the activation, suppression or deviation of host–anti-pathogen immune responses determining the inflammatory pathogenic mechanisms associated with PD.

3. Porphyromonas gingivalis Virulence Factors

With the role of P. gingivalis as the keystone pathogen driving periodontitis, the virulence factors produced by this pathogen play a vital role in bacterial growth and the evasion and modulation of host–anti-pathogen responses, hence adaptation to hostile host–anti-pathogen environments, such as oxidative stress created by respiratory burst activity. Integral to the survival and pathogenesis of this bacterium are the virulence factors fimbriae, LPS, haemolysin, haemagglutinin, gingipains and outer membrane vesicles (OMVs). Fimbriae mediate binding to host cells and the co-aggregation of plaque-forming bacterial species A. naeslundii, S. gordonii and S. oralis. P. gingivalis invades gingival epithelial cells [16], where phagocytosis by these oral epithelial cells induces cell autophagy, enabling bacterial replication, hence persistence, whilst suppressing apoptosis [17]. Fimbria protein subunits exist as long and short forms, namely FimA and Mfa1, respectively [12,13,18,19]. Short fimbriae bind the SspA and SspB proteins of S. gordonii, hence further facilitating bacterial aggregation and biofilm formation [12,20]. Relevant to PD, these short fimbriae also induce osteoclast (OC) differentiation and enhance bone resorption via the production of IL-1β, TNFα, IL-6 and RANKL [12,21]. Long FimA subunits, on the other hand, bind host tissues and epithelial cells via interaction with glycoproteins, fibrinogen, fibronectin, hydroxyapatite and lactoferrin [12,22,23]. In addition, long fimbriae are also capable of facilitating resistance to the innate immune complement system [12] and binding TLR2, hence initiating an inflammatory response mediated via the production and secretion of a plethora of cytokines (including IL-1β, IL-6, IL-8, TNFα) (Section 4), as well as the selective impairment of IL-12 production, with a consequential suppression of Th1 activation and cell-mediated immunity (CMI) impacting bacterial clearance [24]. The mechanism by which long fimbriae, FimA, impair IL-12 is dependent on their binding partner; they can bind the complement receptor, CR3, which inhibits TLR-2-induced IL-12 via an ERK MAPK-dependent system [25,26]. Additionally, binding CXCR4 can cross-regulate TLR-2-mediated signalling by activating a cAMP-dependent PKA response which serves to inhibit NF-kB activation [27], hence suppressing NF-kB-dependent cytokines such as IL-12 and also IL-1β, TNFα, and IL-6.
The cysteine protease gingipains Rgp and Kgp produced by P. gingivalis are capable of degrading the extracellular matrix (e.g., collagen), cytokines, immunoglobulins and complement components [28], participating in bacterial co-aggregation, biofilm formation, the suppression of clotting, capillary permeability and the increased bleeding of periodontal tissues. Gingipains can also regulate host immunity by the degradation of the antimicrobial peptides (AMPs) α- and β-defensins; the down-regulation of macrophage CD14 expression; and the digestion of C3, C4 and C5 complement [29], hence suppressing inflammation whilst reducing bacterial elimination.
Critical to the survival of P. gingivalis is the supply of iron. The virulence factors haemolysin and haemagglutinin help liberate a supply of haem, which is a vital source of iron, for the survival and replication, and hence virulence, of this pathogen. Haem can be released from haemoglobin by the proteolytic activity of another key virulence factor, the gingipain Kgp [30,31,32,33]; hence P. gingivalis takes advantage of inflammatory bleeding by utilizing the virulence factors fimbriae, haemagglutinin, haemolysin and gingipains to agglutinate and haemolyze red blood cells, key to this liberation of iron. Finally, the availability of iron–haem directly affects the structure of LPS, hence its potency of inducing an inflammatory reaction by the innate immune system.
Both iron availability and gingipain functionality overlap at the level of expression, structure and functional potency of the Gram-negative bacterial pathogen-associated molecular pattern (PAMP) Lipopolysaccharide (LPS). As a consequence of iron availability, LPS can exist in distinct structural isoforms which are determined by their level of acylation (acyl chains of lipid A fatty acids) or degree of phosphorylation. In fact, haemin availability has been suggested to trigger the switch in P. gingivalis lipid A structure [34,35], and these lipid A modifications may influence haem availability [36]. Low haem levels result in the expression of the strong immunogenic penta-acylated LPS-1690, whereas higher concentrations induce the weaker immunogenic tetra-acylated LPS 1435/1449 form [37]. P. gingivalis LPS (PG-LPS) is known to signal through TLR4 and is associated with periodontal bone loss [12,38,39]; however, the LPS isoform determines the inflammatory response whereby, based on their proteomic mass:charge ratio, LPS1690 activates inflammatory pathways via NF-kB and p38 MAPK and reduces the intracellular survival of P. gingivalis, through its ability to induce human β-defensins-1, -2 and -3, whereas LPS1435/1449 is known to avoid the inflammatory response and possibly acts as a competitive inhibitor to TLR4-mediated inflammation and suppresses AMP production [40], as a protective evasion mechanism.
P. gingivalis also expresses a secreted peptidyl arginine deiminase (PPAD) enzyme, a virulence factor that modifies proteins by the process of the deimination of arginine, which converts it to citrulline [41,42,43]. This citrullination modifies the host protein structure, which can activate the immune system by exposure to DAMPs or by altered self-inducing autoimmunity [44,45], with this break in self-tolerance resulting in the production of ACPAs in PD [46]. In fact, the resulting citrullinated peptides of fibrinogen and a-enolase have been described as major auto-antigens associated with RA [44]. The effects of the PPAD citrullination of host proteins further benefits the virulence and survival of P. gingivalis by modifying innate defences and barrier functionality, where citrullinated C5a exhibits a loss of function which impacts its ability to initiate inflammatory mechanisms [47], and citrullinated EGF results in breaking epithelial–periodontal tissue barriers [43]. As such, PPAD and other virulence factors play a significant role in the immunopathogenesis of P. gingivalis infection in PD.

4. PD Immunopathology and Immune Response to P. gingivalis

PD inflammation progresses from a local response to a chronic inflammatory lesion and is associated with the dysbiosis of the oral microbiome [48,49,50]. The combined contribution of bacterial co-infection, biofilm formation and localized tissue-specific environmental control of virulence factors has a profound effect on the modulation of host immune responses to P. gingivalis, and these subverted responses characterize the relapsing–remitting nature of this chronic inflammatory pathology with an ever-changing effect on the oral microbiome and virulence of this pathogen. Inflammation increases the availability of haem, iron and metabolic products which favour a hypoxic/anaerobic environment with knock-on effects altering the proportion of Gram-negative proteolytic red complex bacteria [51,52,53,54]. As such, this hinders the understanding of whether dysbiosis triggers the inflammatory response or is a consequence of acute inflammation, contributing to the perpetuation of a chronic inflammatory response. Thus, the bi-directional crosstalk between the oral microbiome and host immune cells dictates this changing in inflammatory response to benefit either the host or pathogen. During the progression of PD, host immune responses are characterized by dysregulated innate inflammatory responses with knock-on effects and changes between cell-mediated immunity, humoral responses and the immune regulation/suppression of adaptive immunity that contribute at different stages of PD to characterize the relapsing/remitting nature of this pathology.
Within days of plaque accumulation, the bacterial PAMPs peptidoglycan (PGN) and lipoteichoic acid (LTA) of early colonizing Gram-positive aerobic bacteria activate complement, inducing the anaphylatoxins C3a and C5a, which trigger mast cell activation and the consequent vascular permeability and oedematous inflammation [55]. Integral to the triggering and initiation of acute inflammation, gingivitis and its progression towards periodontitis make up the dysregulated response of innate immune cells such as neutrophils (Nϕs) and macrophages (Mϕs) to P. gingivalis-derived PAMPs and virulence factors. Dependent on the biofilm environment and accessibility to haem, PG-LPS can be synthesized in the two isoforms mentioned above, with distinct consequences for PAMP recognition and inflammatory responsiveness. In general, P. gingivalis-derived PAMPs, such as fimbriae and LPS, activate tissue-resident epithelial cells and immune cells (Mϕs, Nϕs, mast cells and DCs); this results in these innate cells secreting a plethora of immune-modulatory cytokines that exhibit both pro-inflammatory (IL-1α, IL-1β, IL-6, IL-8, IL-12, IL-18) and anti-inflammatory (IL-6, IL-10, IL-11, IL-35) behaviour [Table 1]. Chemokine expression (IL-8, MCP-1, MIP-1α) induces an influx of Nϕs and monocytes which serve to amplify this inflammatory response and drive chronic inflammation. This persistence is facilitated by infiltrating Nϕs, through enhanced chemokine expression, arachidonate metabolites, proteolytic enzymes (matrix metalloproteinases, MMPs), NET (neutrophil extracellular trap) formation and the release of reactive oxygen species (ROS) [56]. In addition, Mϕ inflammasome activation results in enhanced maturation and secretion of IL-1β/IL-18, as well as inducing pyroptosis, which is an inflammatory cell death characterized by the release of danger-associated molecular patterns (DAMPs) that perpetuate inflammatory initiation through PRR signalling.
The immunopathology of established gingival lesion and chronic inflammatory responses is determined by this initial acute response and the persistence of virulence factors, PAMPs, DAMPs and the resulting immune cells recruited and activated in the oral mucosae. This immune–oral microbiome axis is integral to determining the ensuing adaptive immune responses elicited in this mucosal tissue, which is dependent on the cytokine profiles elicited in response to such pathogens as P. gingivalis. The cytokines produced and detected in saliva, GCF and oral mucosal tissue are summarized in Table 1, and they drive the recruitment and activation of innate immune cells (Nϕs, Mϕs, DCs, mast cells) and adaptive immune cells (Th1, Th2, Th17, Tr and B cells), with a shift away from Nϕ involvement and a consequent prevalence of Mϕ and lymphocyte (both T- and B-cell) involvement [119,120].
Th1 may be considered bacterial-resolving and secrete IFNγ and TNFα upon differentiation by IL-12; these cells effectively activate and differentiate pro-inflammatory M1 macrophage subsets, resulting in a tissue-destructive DTH (delayed-type hypersensitivity) response and Nϕ NET formation. PG-LPS has been described to influence Th2 differentiation and activation which, in an IL-4-rich environment, drives Mϕ polarization to an M2 subset, as well as B-cell activation and antibody secretion by plasma cells. Such subversion of Th1 to Th2 effectively changes the P. gingivalis-clearing CMI response to a less efficient humoral response, facilitating the persistence of P. gingivalis infection [121,122,123] and disease progression [124]. Historically, PD and its development and prognosis were considered to be determined by a Th1/Th2 paradigm; this has since been overtaken by the realization of a plastic inter-relation between Th17 and Treg subsets, where an intermediary phenotype of IL-17+/FoxP3+ cells (Treg to Th17 conversion) has been suggested to be present in periodontitis lesions [125]. Finally, with the persistence of P. gingivalis, the adaptive response progresses, in the presence of IL-6 and IL-23, to a Th17-driven mechanism [126]. Th17 cells are expanded in PD and secrete GM-CSF, TNFα, IL-21, IL-22 and IL-17, which potently activate Mϕs and Nϕs, perpetuating a cycle of tissue-destructive inflammation [127]. In fact, one of the end-stage factors associated with PD is the resorption and loss of alveolar bone, subsequently resulting in tooth loss. With the collaboration of both innate and adaptive cells, pro-inflammatory cytokines such as IL-1β and TNFα have been described to up-regulate RANKL, which can be secreted or expressed on the surface of Th1, Th17, B cells, osteoblasts (OBs) and natural killer T cells (NKTs), activating osteoclast (OC)-mediated bone resorption upon RANK ligation. Such RANKL-RANK-mediated OC bone resorption activity can be antagonized by OPG, a decoy receptor effectively inhibiting RANKL-RANK reception; future research may investigate the manipulation of such an OPG:RANKL ratio to control alveolar bone loss in PD [128].
The involvement of Th1, Th17 and Th2 cells may indicate the range of pro-inflammatory mechanisms involved in PD but fail to fully explain the episodes of remission where inflammatory destruction is effectively quiescent or actively suppressed. There are potentially several pathways by which these inflammatory mechanisms are tolerized or subverted: these include (i) negative regulation of TLR-induced pro-inflammatory Mϕs or endotoxin tolerization (ET); (ii) Mϕ subset plasticity—changing the M1 Mϕ subset to an anti-inflammatory M2 subset; and (iii) an Mϕ/APC cytokine profile exhibiting a TGFβ/IL-10 predominance with consequential differentiation favouring Tregs. Such immune-suppressive or immune deviation mechanisms are integral to the evasion strategies harnessed by P. gingivalis to ensure its persistence and may represent future therapeutic targets to control PD.

5. Immune Evasion

Rather than simply triggering inflammation, P. gingivalis is skilled with evasion mechanisms to modulate both host innate and adaptive immunity [129], allowing it to persist and promote a dysbiotic biofilm and continue in its destructive path [130]. Early innate defenders, including Nϕs and Mϕs, are undermined through subversive signalling [131]. Central to this activity are the arginine- and lysine-specific cysteine proteases, gingipains. Gingipains have been demonstrated to alter Nϕ function by increasing ROS, reducing Nϕ elastase (a serine protease required for microbial killing), and suppressing the expression of the Nϕ chemotactic cytokine IL-8 [132]. These changes suggest that gingipains diminish Nϕ recruitment and elastase-mediated killing, thereby facilitating P. gingivalis immune evasion, hence the persistence of this keystone pathogen. One study also showed that P. gingivalis prolongs Nϕ survival by up-regulating antiapoptotic BCL-2 family proteins. Although this effect was not directly gingipain-dependent, it likely contributes to the chronic inflammatory environment in which P. gingivalis thrives. These apparent contradictions in Nϕ involvement; diminished recruitment, yet increased survival, increased ROS production but reduced elastase, may be explained by both stage of PD progression and the evasion strategies employed by this bacterium. This probably reflects the early recruitment, activation and antimicrobial killing activity of Nϕs, whereas with the progression of PD and deployment of evasion strategies, P. gingivalis modulates Nϕ-mediated immunity in its favour, reducing recruitment, increasing the survival of killing-incompetent cells, and diminishing the levels of elastase yet being able to maintain a bacterial-supportive inflammatory environment.
Gingipains have similarly been connected to the suppression of dendritic cell activation [133]. However, the P. gingivalis strain W50 lacks this suppressive effect due to a HagA point mutation that disrupts the PorSS/gingipain secretion system, highlighting strain-specific differences in gingipain-mediated immune evasion. Gingipains additionally contribute to vascular dysfunction, where P. gingivalis degrades platelet endothelial cell adhesion molecule-1 (PECAM-1 or CD31), compromising endothelial integrity; increasing permeability, hence vascular leakage; and enabling the translocation of other bacteria [134]. Although infection enhances monocyte adhesion, gingipains impair their trans-endothelial migration by down-regulating CD99 and CD99L2 on endothelial cells and monocytes, indicating the disruption of normal immune cell trafficking.
P. gingivalis also thrives by uncoupling TLR2-driven inflammation from effective bacterial clearance. P. gingivalis also exploits the integrin-associated protein CD47, a ‘don’t eat me’ signal associated with some cancers, that suppresses phagocytic clearance via its interaction with the negative regulatory receptor SIRP-1a [135]. CD47 interacts with TLR2 to promote cell survival, whereas CD47 deficiency enhances Mϕ bacterial clearance. P. gingivalis further induces the secretion of thrombospondin-1 (TSP-1), a CD47 ligand that suppresses Nϕ bactericidal activity in relation to PD-associated bacteria. TLR2–CD47 co-signalling and TSP-1 induction suggest a major immune evasion pathway supporting P. gingivalis persistence. In fact, TSP-1 is elevated in the gingival crevicular fluid (GCF) of patients with PD and in inflamed gingiva in animal models, with PG-LPS driving its production [136]. In periodontal fibroblasts, TSP-1 promotes the expression of MMP-2 and MMP-9 and an increased RANKL/OPG ratio, all contributing to extracellular matrix degradation and bone resorption, while its inhibition suppresses cytokine production in PG-LPS-stimulated Mϕs. By amplifying inflammation and tissue destruction without improving bacterial clearance, TSP-1 supports a dysbiotic environment favourable to P. gingivalis.
P. gingivalis can establish the evasion of host defence mechanisms via a combination of immune suppression and immune deviation. The innate immune system can be deviated or suppressed by multiple simulation of PRRs through endotoxin tolerization (ET). Which mechanism predominates is likely dictated by the local environment determined by the stage of dysbiosis and immune response. P. gingivalis evades host defences through modifications of its LPS, including tetra-acylated and monophosphorylated lipid A forms [137,138], which act as weak TLR4 agonists, resulting in a reduced TLR-4-mediated induction of AMPs involved in epithelial defences and reduced inflammasome activation [139]. PG-LPS weakly activates the M1 and M2 Mϕ expression of pro-inflammatory cytokines and costimulatory molecules, whereas it elevates Arginase I expression in M2, in a PG-LPS isoform-dependent manner [140]. Such LPS-induced effects are capable of reducing the pro-inflammatory responses of M1 Mϕs while increasing M2 polarization, hence biasing towards an anti-inflammatory response and facilitating bacterial persistence, through a process of immune deviation. P. gingivalis-OMV gingipains mediate Mϕ CD14 loss, hence a reduction in TLR4-LPS responsiveness [141]. In contrast to this suppressive mechanism associated with OMV gingipains, P. gingivalis OMVs are enriched in C4′-monophosphoryl lipid A (C4′-MPLA), a potent TLR4 agonist that stimulates IFNβ and IL-1β production while diverting immune recognition away from the bacterium itself, suggestive of immune deviation rather than suppression [142]. Strains producing more OMVs (e.g., PG381) generated stronger pro-inflammatory responses. AMPs such as Cathelicidin (LL-37) blocked OMV-induced TLR4 signalling, confirming the immunostimulatory role of C4′-MPLA; however, PG NPLA-containing OMVs resist LL-37-mediated killing. Finally, studies focused on ET have demonstrated Mϕ subsets to exhibit differential sensitivity to ET induced by PG-LPS, where M2 Mϕs (anti-inflammatory subset) are selectively tolerized, and M1 Mϕs (pro-inflammatory subset) are refractory to tolerance induction, with respect to the induction of TNFα [143], whereas ET induced by repeated stimulation with E. coli K-12 LPS resulted in a uniform suppression of TNFα between both Mϕ subsets yet differing effects on IL-6 and IL-10 in a manner associated with the differential subset-specific expression of the negative regulators IRAK-M and Tollip [144].
In addition to the above, other established immune evasion strategies of P. gingivalis include immune deviation to adaptive immunity, with respect to T-cell responses, where Th17 is favoured over Treg immunity, due to the gingipain inhibition of IL-2- and IL-12-dependent Th1 differentiation [145]. T cells can also be suppressed, where PG-LPS was found to induce IDO expression in human gingival fibroblasts, which resulted in the indirect tolerization of T cells [146]. Recent evidence shows that P. gingivalis also manipulates host gene regulation to evade immunity. An RNA-seq analysis of wildtype- and gingipain-deficient P. gingivalis-stimulated Mϕs revealed widespread changes in alternative splicing, including the increased expression of the negative-regulatory PD-L1 and a preferential shift towards a PD-L1 isoform with higher PD-1 binding affinity, thus impairing and tolerizing adaptive immune T-cell function [147].

6. Current Treatments for Periodontitis

Depending on the advancement of the disease, less invasive procedures include scaling, root planing (smoothing of root surfaces to minimize bacterial attachment) and courses of antibiotics [148]. However, if PD is advanced, then more invasive treatments are required, and these increase in terms of severity, including pocket reduction surgery, soft tissue grafts, bone grafts, and guided tissue regeneration using both natural and synthetic biomaterials [149,150]. More recently, light-activated compounds have been utilized as a non-surgical treatment in the form of antimicrobial photodynamic therapy (aPDT) [151], and a variety of growth factors, e.g., Emdogain (containing enamel matrix proteins to help regenerate lost tissue) have also been applied [152]. As such, the current therapeutic approaches are focused on tissue replacement, regeneration and antimicrobial targeting; there is a huge gap between our understanding of the cellular and molecular immunopathological mechanisms driving PD and the translation to adopt potential immune-modulatory therapies.

7. Summary and Future Perspectives

The immunopathological mechanisms underlying the chronic destructive nature of PD are a complex network of dysregulated innate and adaptive immune responses in an attempt to clear pathological bacteria such as P. gingivalis that present as keystone pathogens resulting from inflammation and its reciprocal relationship to the dysbiosis of the oral microbiome (Figure 1). PD starts with an uncontrolled innate response mediated by Nϕs and Mϕs that result in a pro-inflammatory cytokine profile unregulatable by anti-inflammatory cytokines. These cytokine profiles and cycling between activatory and suppressive environments effectively explain the bouts of relapse and remission in the inflammatory response. During episodes of remission, ET is likely involved, which may be of benefit to the host by limiting destructive inflammatory mechanisms, but at the same time, it may be of benefit to the pathogen to allow it to recoup its numbers. This poses the question, who is ET good for? Host or pathogen? In such locations where the cytokine profile may be under continuous change depending on the local tissue environment, P. gingivalis virulence factors contribute to the profiles, which may play an important role in subverting a potentially pathogen-clearing Th1-mediated response to that of a Th2 humoral response that facilitates pathogen persistence. Couple this with the observations that virulence factors affect cytokine profiles; then changes in these molecules go some way to explain the emergence of Th17-mediated Nϕ activation and alveolar bone-destructive mechanisms at the expense of Treg-mediated immune tolerance and the suppression of destructive inflammation. As a consequence, PD and its inflammatory network are driven by a complexity of host factors from both innate and adaptive immunity, which is governed by a cycle of host inflammatory molecules, which in turn control the dysbiosis and predominance of pathogens such as P. gingivalis and their virulence factors, as well as cycling back to modulate host immunity to the advantage of the pathobiont.
P. gingivalis employs a diverse and highly coordinated collection of immune evasion strategies that target multiple branches of host defence; however, its influence remains elusive. Continued research is therefore essential to fully understand these pathways and identify potential therapeutic strategies to target immune evasion strategies employed by P. gingivalis, hence bacterial persistence and immune subversion resulting in a chronic inflammatory state. Gingipains manipulate complement activation, the phagocytic killing of infected cells, Nϕ activation and elastase/IL-8 production and cytokine skewing towards Th17, rather than Treg; the inhibition of such gingipain-mediated responses would appear to present as a valid treatment regimen [131,132,153]. Additionally, the antagonism of fimbria-induced responses, such as blocking CR3, may represent an appropriate approach to reconstituting IL-12 production, hence Th1-cell mediated responses for appropriate pathogen killing and clearance [25]. The understanding of the dynamics between pathogen expression and host responsiveness to PG-LPS is likely to indicate further therapeutic routes for the treatment of PD, but what is required? PG-LPS modification and the stimulation of TLR4-mediated inflammatory responses are required, leading to clearance mechanisms dependent on cell-mediated immunity or the induction of AMPs such as LL-37 and β-defensins [154]. If the balance is incorrect and tipped in favour of clearance activatory mechanisms, this may result in an over-zealous pro-inflammatory effect that is destructive to host tissue and may alter pathobiont dominance, hence leading to a deviation in the immune response required for microbial clearance. Conversely, if PG-LPS response potency is weak or indeed it induces a predominant ET response, this may temper tissue-destructive host inflammation but also favour bacterial growth and persistence. Thus, the manipulation of ET may only be used at the appropriate stage in PD progression or the relapse–remission cycle. Controversially, it may be considered that ET may not be involved in this pathology and that episodes of quiescence may alternatively represent periods of Mϕ polarization plasticity, effectively converting pro-inflammatory cells to anti-inflammatory cells and visa versa, with downstream implications for cytokine profiles. These cytokines are sensitive to degradation by P. gingivalis-containing biofilms [155] with regard to gingipain production and other proteinases; as such, the future therapeutic targeting of cytokine production and functionality will have to consider the expression and activity of these enzymes—possibly rationalizing a combination therapeutic approach. Finally, OMVs contain a wealth of P. gingivalis-associated PAMPs and virulence factors, exhibiting both immune activatory and suppressive effects; such OMVs have been suggested as vaccine components to resist the accumulation of this keystone pathogen [156]. Overall, the therapeutic treatment of PD can only be achieved by obtaining a comprehensive understanding of the immune–microbiome axis: the complete understanding of the bacterial activation of innate immunity, the cytokine profiles elicited, the early effects of dysbiosis and the cycling between bouts of inflammatory activation and tolerization allow for an appreciation for PD progression, utilizing adaptive immune mechanisms. These adaptive responses, which change from Th1-driven CMI to Treg/Th17 plasticity, result in further tissue destruction and, finally, Th2-B-cell humoral responses. As such, the immunopathological mechanisms driving PD and the pathogen-derived evasion strategies modulating host defences are highly variable and dependent on the stage of progression. The appreciation of these specific host–pathogen mechanisms at distinct stages may clarify novel therapeutic approaches in the treatment of PD.

Author Contributions

Conceptualization, A.F., S.R. and V.S.; methodology, A.F. and V.S.; software, A.F. and S.R.; validation, A.F., V.S. and S.R.; formal analysis, A.F.; investigation, A.F., V.S. and S.R.; resources, A.F., V.S. and A.S.; data curation, A.F. and S.R.; writing—original draft preparation, A.F., V.S., S.R. and A.S.; writing—review and editing, A.F., V.S. and S.R.; visualization, A.F., V.S. and V.S.; supervision, A.F. and V.S.; project administration, A.F. and V.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Deo, P.N.; Deshmuksh, R. Oral microbiome: Unveiling the fundamentals. J. Oral Max. Path. 2019, 23, 122–128. [Google Scholar] [CrossRef] [PubMed]
  2. Nazir, M.A. Prevalence of periodontal disease, its association with systemic diseases and prevention. Int. J. Health Sci. 2017, 11, 72–80. [Google Scholar]
  3. Nascimento, G.G.; Costa, S.A.; Romandini, M. Burden of severe periodontitis and edentulism in 2021, with projections up to 2050: The global burden of disease 2021 study. J. Periodont. Res. 2024, 59, 823–867. [Google Scholar] [CrossRef]
  4. Irani, S.; Barati, I.; Badiei, M. Periodontitis and oral cancer—Current concepts of the etiopathogenesis. Oncol. Rev. 2020, 14, 23–34. [Google Scholar] [CrossRef]
  5. Caton, J.G.; Armitage, G.; Berglundh, T.; Chapple, I.L.C.; Jepsen, S.; Kornman, K.S.; Mealey, B.L.; Papapanou, P.N.; Sanz, M.; Tonetti, M.S. A new classification scheme for periodontal and peri-implant diseases and conditions—Introduction and key changes from the 1999 classification. J. Perio. 2018, 89, S1–S8. [Google Scholar] [CrossRef]
  6. How, K.Y.; Song, K.P.; Chan, K.G. Porphyromonas gingivalis: An Overview of Periodontopathic Pathogen below the Gum Line. Front. Microbiol. 2016, 9, 53. [Google Scholar] [CrossRef]
  7. Tattar, R.; da Costa, B.; Neves, V. The interrelationship between periodontal disease and systemic health. Br. Dent. J. 2025, 239, 103–108. [Google Scholar] [CrossRef]
  8. Meuric, V.; Le Gall-David, S.; Boyer, E.; Acuna-Amador, L.; Martin, B.; Fong, S.B.; Barloy-Hubler, F.; Bonnaure-Mallet, M. Signature of microbial dysbiosis in periodontitis. Appl. Environ. Microbiol. 2017, 83, e00462-17. [Google Scholar] [CrossRef]
  9. Mohanty, R.; Asopa, S.J.; Joseph, M.D.; Singh, B.; Rajguru, J.P.; Saidath, K.; Sharma, U. Red complex: Polymicrobial conglomerate in oral flora: A review. J. Fam. Med. Prim. Care 2019, 8, 3480. [Google Scholar] [CrossRef] [PubMed]
  10. Bourgeois, D.; Inquimbert, C.; Ottolenghi, L.; Carrouel, F. Periodontal pathogens as risk factors of cardiovascular diseases, diabetes, rheumatoid arthritis, cancer and chronic obstructive pulmonary disease—Is there cause for consideration? Microorganisms 2019, 7, 424. [Google Scholar] [CrossRef] [PubMed]
  11. Bui, F.Q.; Almeida-da-Silva, C.L.C.; Huynh, B.; Trinh, A.; Liu, J.; Woodward, J.; Asadi, H.; Ojcius, D.M. Association between periodontal pathogens and systemic disease. Biomed. J. 2019, 42, 27–35. [Google Scholar] [CrossRef]
  12. Xu, W.; Zhou, W.; Wang, H.; Liang, S. Roles of Porphyromonas gingivalis and its virulence factors in periodontitis. Adv. Protein Chem. Struct. Biol. 2020, 120, 45–84. [Google Scholar] [CrossRef]
  13. Hasegawa, Y.; Nagano, K. Porphyromonas gingivalis FimA and Mfa1 fimbriae: Current insights on localisation, function, biogenesis and genotype. Jpn. Dent. Sci. Rev. 2021, 57, 190–200. [Google Scholar] [CrossRef]
  14. Slots, J. Periodontitis: Facts, fallacies and the future. Periodontology 2000 2017, 75, 7–23. [Google Scholar] [CrossRef]
  15. Kinane, D.F.; Stathopoulou, P.G.; Papapanou, P.N. Periodontal diseases. Nat. Rev. Dis. Primers 2017, 3, 17038. [Google Scholar] [CrossRef] [PubMed]
  16. Lamont, R.J.; Chan, A.; Belton, C.M.; Izutsu, K.T.; Vasel, D.; Weinberg, A. Porpyromonas gingivalis invasion of gingival epithelial cells. Infect. Immun. 1995, 63, 3878–3885. [Google Scholar] [CrossRef] [PubMed]
  17. Nakhjiri, S.F.; Park, Y.; Yilmaz, O.; Chung, W.O.; Watanabe, K.; El-Sabaeny, A.; Park, K.; Lamont, R.J. Inhibition of cell apoptosis by Porphyromonas gingivalis. FEMS Microbiol. Lett. 2001, 200, 145–149. [Google Scholar] [CrossRef]
  18. Amano, A. Host-parasite interactions in periodontitis: Microbial pathogenicity and innate immunity. Periodontology 2000 2010, 54, 9–14. [Google Scholar] [CrossRef]
  19. Ogawa, T.; Mukai, T.; Yasuda, K.; Shimauchi, H.; Toda, Y.; Hamada, S. Distribution and immunochemical specificities of fimbriae of Porphyromonas gingivalis and related bacterial species. Oral Microbiol. Immunol. 1991, 6, 332–340. [Google Scholar] [CrossRef]
  20. Lamont, R.J.; Hsiao, G.W.; Gil, S. Identification of a molecule of Porphyromonas gingivalis that binds to Streptococcus. Microb. Pathog. 1994, 17, 355–360. [Google Scholar] [CrossRef] [PubMed]
  21. Jia, L.; Han, N.; Du, J.; Guo, L.; Luo, Z.; Liu, Y. Pathogenesis of important virulence factors of Porphyromonas gingivalis via Toll-like receptors. Front. Cell. Infect. Microbiol. 2019, 9, 262. [Google Scholar] [CrossRef]
  22. Amano, A. Molecular interaction of Porphyromonas gingivalis with host cells: Implication for the microbial pathogenesis of periodontal disease. J. Periodontol. 2003, 74, 90–96. [Google Scholar] [CrossRef]
  23. Hamada, N.; Sojar, H.T.; Cho, M.I.L.; Genco, R.J. Isolation and characterisation of a minor fimbriae from Porphyromonas gingivalis. Infect. Immun. 1996, 64, 4788–4794. [Google Scholar] [CrossRef]
  24. Jauregui, C.E.; Wang, Q.; Wright, C.J.; Takeuchi, H.; Uriarte, S.M.; Lamont, R.J. Suppression of T-Cell Chemokines by Porphyromonas gingivalis. Infect. Immun. 2013, 81, 2288–2295. [Google Scholar] [CrossRef] [PubMed]
  25. Hajishengallis, G.; Shakhatreh, M.-A.K.; Wang, M.; Liang, S. Complement Receptor 3 Blockade Promotes IL-12-Mediated Clearance of Porphyromonas gingivalis and Negates Its Virulence In Vivo. J. Immunol. 2007, 179, 2359–2367. [Google Scholar] [CrossRef] [PubMed]
  26. Hajishengallis, G.; Lambris, J.D. Microbial manipulation of receptor crosstalk in innate immunity. Nat. Rev. Immunol. 2011, 11, 187–200. [Google Scholar] [CrossRef]
  27. Hajishengallis, G.; Wang, M.; Liang, S.; Triantafilou, M.; Triantafilou, K. Pathogen induction of CXCR4/TLR2 cross-talk impairs host defence function. Proc. Natl. Acad. Sci. USA 2008, 105, 13532–13537. [Google Scholar] [CrossRef]
  28. Bostanci, N.; Belibasakis, G.N. Porphyromonas gingivalis: An invasive and evasive opportunistic oral pathogen. FEMS Microbiol. Lett. 2012, 333, 1–9. [Google Scholar] [CrossRef]
  29. Jagels, M.A.; Ember, J.A.; Travis, J.; Potempa, J.; Pike, R.; Hugli, T.E. Cleavage of the human C5A receptor by proteinases derived from Porphyromonas gingivalis: Cleavage of leukocyte C5a receptor. Adv. Exp. Med. Biol. 1996, 389, 155–164. [Google Scholar] [CrossRef]
  30. Smalley, J.W.; Olczak, T. Heme acquisition mechanisms of Porphyromonas gingivalis—Strategies used in a polymicrobial community in a heme-limited host environment. Mol. Oral Microbiol. 2017, 32, 1–23. [Google Scholar] [CrossRef] [PubMed]
  31. Smalley, J.W.; Birss, A.J.; Withnall, R.; Silver, J. Interactions of Porphyromonas gingivalis with oxyhaemoglobin and deoxyhaemoglobin. Biochem. J. 2002, 362, 239–245. [Google Scholar] [CrossRef]
  32. Smalley, J.W.; Birss, A.J.; Szmigielski, B.; Potempa, J. Sequential action of R- and K-specific gingipains of Porphyromonas gingivalis in the generation of the haem-containing pigment from oxyhaemoglobin. Arch. Biochem. Biophys. 2007, 465, 44–49. [Google Scholar] [CrossRef] [PubMed]
  33. Smalley, J.W.; Birss, A.J.; Szmigielski, B.; Potempa, J. Mechanism of methaemoglobin breakdown by the lysine-specific gingipain of the periodontal pathogen Porphyromonas gingivalis. Biol. Chem. 2008, 389, 1235–1238. [Google Scholar] [CrossRef] [PubMed]
  34. Al-Qutub, M.N.; Braham, P.H.; Karimi-Naser, L.M.; Liu, X.; Genco, C.A.; Darveau, R.P. Hemin-dependent modulation of the lipid A structure of Porphyromonas gingivalis lipopolysaccharide. Infect. Immun. 2006, 74, 4474–4485. [Google Scholar] [CrossRef] [PubMed]
  35. Coats, S.R.; Jones, J.W.; Do, C.T.; Braham, P.H.; Bainbridge, B.W.; To, T.T.; Goodlett, D.R.; Ernst, R.K.; Darveau, R.P. Human Toll-like receptor 4 responses to P. gingivalis are regulated by lipid A 1- and 4′-phosphatase activities. Cell Microbiol. 2009, 11, 1587–1599. [Google Scholar] [CrossRef]
  36. Olczak, T.; Sosicka, P.; Olczak, M. HmuY is an important virulence factor for Porphyromonas gingivalis growth in the heme-limited host environment and infection of macrophages. Biochem. Biophys. Res. Comms 2015, 467, 748–753. [Google Scholar] [CrossRef]
  37. Jain, S.; Darveau, R.P. Contribution of Porphyromonas gingivalis lipopolysaccharide to periodontitis. Periodontology 2000 2010, 54, 53–70. [Google Scholar] [CrossRef]
  38. Papadopoulos, G.; Weinberg, E.O.; Massari, P.; Gibson, F.C.; Wetzler, L.M.; Morgan, E.F.; Genco, C.A. Macrophage-specific TLR2 signalling mediates pathogen-induced TNF-dependent inflammatory oral bone loss. J. Immunol. 2013, 190, 1148–1157, Erratum in J. Immunol. 2022, 209, 1617. https://doi.org/10.4049/jimmunol.2200589. [Google Scholar] [CrossRef]
  39. Wang, P.L.; Ohura, K. Porphyromonas gingivalis lipopolysaccharide signalling in gingival fibroblasts—CD14 and Toll-like receptors. Crit. Rev. Oral Biol. Med. 2002, 13, 132–142. [Google Scholar] [CrossRef]
  40. Lu, Q.; Darveau, R.P.; Samaranayake, L.P.; Wang, C.Y.; Jin, L. Differential modulation of human beta-defensins expression in human gingival epithelia by Porphyromonas gingivalis lipopolysaccharide with tetra- and penta-acylated lipid A structures. Innate Immun. 2009, 15, 325–335. [Google Scholar] [CrossRef]
  41. McGraw, W.T.; Potempa, J.; Farley, D.; Travis, J. Purification, characterisation, and sequence analysis of a potential virulence factor from Porphyromonas gingivalis, peptidylarginine deiminase. Infect. Immun. 1999, 67, 3248–3256. [Google Scholar] [CrossRef]
  42. Rodriguez, S.B.; Stitt, B.L.; Ash, D.E. Expression of peptidylarginine deiminase from Porphyromonas gingivalis in Escherichia coli: Enzyme purification and characterisation. Arch. Biochem. Biophys. 2009, 488, 14–22. [Google Scholar] [CrossRef] [PubMed][Green Version]
  43. Pyrc, K.; Milewska, A.; Kantyka, T.; Sroka, A.; Maresz, K.; Koziel, J.; Nguyen, K.-A.; Enghild, J.J.; Knudsen, A.D.; Potempa, J. Inactivation of epidermal growth factor by Porphyromonas gingivalis as a potential mechanism for periodontal tissue damage. Infect. Immun. 2013, 81, 55–64. [Google Scholar] [CrossRef]
  44. Wegner, N.; Lundberg, K.; Kinloch, A.; Fisher, B.; Malmstrom, V.; Feldmann, M.; Venables, P.J. Autoimmunity to specific citrullinated proteins gives the first clues to etiology of rheumatoid arthritis. Immunol. Rev. 2010, 233, 34–54. [Google Scholar] [CrossRef] [PubMed]
  45. Potempa, J.; Mydel, P.; Koziel, J. The case for periodontitis in the pathogenesis of rheumatoid arthritis. Nat. Rev. Rheumatol. 2017, 13, 606–620. [Google Scholar] [CrossRef]
  46. Hendler, A.; Mulli, T.K.; Hughes, F.J.; Perrett, D.; Bombardieri, M.; Houri-Haddad, Y.; Weiss, E.I.; Nissim, A. Involvement of autoimmunity in the pathogenesis of aggressive periodontitis. J. Dent. Res. 2010, 89, 1389–1394. [Google Scholar] [CrossRef]
  47. Bielecka, E.; Scavenius, C.; Kantyka, T.; Jusko, M.; Mizgalska, D.; Szmigielski, B.; Potempa, B.; Enghild, J.J.; Prossnitz, E.R.; Blom, A.M.; et al. Peptidyl arginine deiminase from Porphyromonas gingivalis abolishes anaphylatoxin C5a activity. J. Biol. Chem. 2014, 289, 32481–32487. [Google Scholar] [CrossRef]
  48. Hajishengallis, G.; Lamont, R.J. Beyond the red complex and into more complexity: The polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. Mol. Oral Microbiol. 2012, 27, 409–419. [Google Scholar] [CrossRef] [PubMed]
  49. Baima, G.; Ferrocino, I.; Del Lupo, V.; Colonna, E.; Thumbigere-Math, V.; Caviglia, G.P.; Franciosa, I.; Mariani, G.M.; Romandini, M.; Ribaldone, D.G.; et al. Effect of periodontitis and periodontal therapy on oral and gut microbiota. J. Dent. Res. 2024, 103, 359–368. [Google Scholar] [CrossRef]
  50. Mira, A.; Simon-Soro, A.; Curtis, M.A. Role of microbial communities in the pathogenesis of periodontal diseases and caries. J. Clin. Periodontol. 2017, 44, S23–S38. [Google Scholar] [CrossRef]
  51. Mc Nabb, H.; Mombelli, A.; Gmur, R.; Mathey-Dinc, S.; Lang, N. Periodontal pathogens in the shallow pockets of immigrants from developing countries. Oral Microbiol. Immunol. 1992, 7, 267–272. [Google Scholar] [CrossRef] [PubMed]
  52. Griffen, A.; Becker, M.; Lyons, S.; Moeschberger, M.; Leys, E. Prevalence of Porphyromonas gingivalis and periodontal health status. J. Clin. Microbiol. 1998, 36, 3239–3242. [Google Scholar] [CrossRef]
  53. Hajishengallis, G. The inflammophilic character of the periodontitis-associated microbiota. Mol. Oral Microbiol. 2014, 29, 248–257. [Google Scholar] [CrossRef]
  54. Higashi, D.L.; Qin, H.; Borland, C.; Kreth, J.; Merritt, J. An inflammatory paradox: Strategies inflammophilic oral pathobionts employ to exploit innate immunity via neutrophil manipulation. Front. Oral Health 2024, 5, 1413842. [Google Scholar] [CrossRef]
  55. Hajishengallis, G. Periodontitis: From microbial immune subversion to systemic inflammation. Nat. Revs. Immunol. 2015, 15, 30–44. [Google Scholar] [CrossRef]
  56. Kolaczkowska, E.; Kubes, P. Neutrophil recruitment and function in health and inflammation. Nat. Revs. Immunol. 2013, 13, 159–175. [Google Scholar] [CrossRef]
  57. Rossomando, E.F.; Kennedy, J.E.; Hadjimichael, J. Tumour necrosis factor alpha in gingival crevicular fluid as a possible indicator of periodontal disease in humans. Arch. Oral Biol. 1990, 35, 431–434. [Google Scholar] [CrossRef]
  58. Matsuki, Y.; Yamamoto, T.; Hara, K. Detection of inflammatory cytokine messenger RNA (mRNA)-expressing cells in human inflamed gingiva by combined in situ hybridization and immunohistochemistry. Immunology 1992, 76, 42. [Google Scholar] [PubMed]
  59. Bastos, M.F.; Lima, J.A.; Viera, P.M.; Mestnik, M.J.; Faveri, M.; Duarte, P.M. TNF-a and IL-4 levels in generalised aggressive periodontitis subjects. Oral Dis. 2009, 15, 82–87. [Google Scholar] [CrossRef] [PubMed]
  60. Okamatsu, Y.; Kobayashi, M.; Nishihara, T.; Hasegawa, K. Interleukin-1α produced in human gingival fibroblasts induces several activities related to the progression of periodontitis by direct contact. J. Periodont. Res. 1996, 31, 355–364. [Google Scholar] [CrossRef]
  61. Dayan, S.; Stashenko, P.; Niederman, R.; Kupper, T.S. Oral Epithelial Overexpression of IL-1α Causes Periodontal Disease. J. Dent. Res. 2004, 83, 786–790. [Google Scholar] [CrossRef] [PubMed]
  62. Masada, M.P.; Persson, R.; Kenney, J.S.; Lee, S.W.; Page, R.C.; Allison, A.C. Measurement of interleukin-1alpha and -1beta in gingival crevicular fluid: Implications for the pathogenesis of periodontal disease. J. Periodontal Res. 1990, 25, 156–163. [Google Scholar] [CrossRef]
  63. Jandinski, P.; Stashenko, F.; Leung, L.S.; Peros, C.C.; Rynar, J.E.; Deasy, M.J. Localization of Interleukin-lβ in Human Periodontal Tissue. J. Periodontol. 1991, 62, 36–43. [Google Scholar] [CrossRef]
  64. Gemmell, E.; Seymour, G.J. Cytokine Profiles of Cells Extracted from Humans with Periodontal Diseases. J. Dent. Res. 1998, 77, 16–26. [Google Scholar] [CrossRef]
  65. Orozco, A.; Gemmell, E.; Bickel, M.; Seymour, G.J. Interleukin-1 beta, interleukin-12 and interleukin-18 levels in gingival fluid and serum of patients with gingivitis and periodontitis. Oral Microbiol. Immunol. 2006, 21, 256–260. [Google Scholar] [CrossRef]
  66. Kabashima, H.; Nagata, K.; Hashiguchi, I.; Toriya, Y.; Iijima, T.; Maki, K.; Maeda, K. Interleukin-1 receptor antagonist and interleukin-4 in gingival crevicular fluid of patients with inflammatory periodontal disease. J. Oral Pathol. Med. 1996, 25, 449–455. [Google Scholar] [CrossRef] [PubMed]
  67. Rawlinson, A.; Dalati, M.H.N.; Rahman, S.; Walsh, T.F.; Fairclough, A.L. Interleukin-1 and IL-1 receptor antagonist in gingival crevicular fluid. J. Clin. Periodontol. 2000, 27, 738–743. [Google Scholar] [CrossRef] [PubMed]
  68. Gilowski, J.; Wiench, R.; Plocica, I.; Krzeminski, T.F. Amount of interleukin-1β and interleukin-1 receptor antagonist in periodontitis and healthy patients. Arch. Oral Biol. 2014, 59, 729–734. [Google Scholar] [CrossRef]
  69. Lappin, D.F.; MacLeod, C.P.; Kerr, A.; Mitchell, T.; Kinane, D.F. Anti-inflammatory cytokine IL-10 and T cell cytokine profile in periodontitis granulation tissue. Clin. Exp. Immunol. 2001, 123, 294–300. [Google Scholar] [CrossRef]
  70. Pradeep, A.R.; Roopa, Y.; Swati, P.P. Interleukin-4, a T-helper 2 cell cytokine, is associated with the remission of periodontal disease. J. Periodont. Res. 2008, 43, 712–716. [Google Scholar] [CrossRef]
  71. Geivelis, M.; Turner, D.W.; Pederson, E.D.; Lamberts, B.L. Measurements of Interleukin-6 in Gingival Crevicular Fluid from Adults with Destructive Periodontal Disease. J. Periodontol. 1993, 64, 980–983. [Google Scholar] [CrossRef]
  72. Takahashi, K.; Takashiba, S.; Nagai, A.; Takigawa, M.; Myoukai, F.; Kurihara, H.; Murayama, Y. Assessment of Interleukin-6 in the Pathogenesis of Periodontal Disease. J. Periodontol. 1994, 65, 147–153. [Google Scholar] [CrossRef]
  73. Payne, J.B.; Reinhardt, R.A.; Masada, M.P.; DuBois, L.M.; Allison, A.C. Gingival crevicular fluid IL-8: Correlation with local IL-1 beta levels and patient estrogen status. J. Periodont. Res. 1993, 28, 451–453. [Google Scholar] [CrossRef]
  74. Tonetti, M.S.; Imboden, M.A.; Lang, N.P. Neutrophil Migration into the Gingival Sulcus Is Associated with Transepithelial Gradients of Interleukin-8 and ICAM-1. J. Periodontol. 1998, 69, 1139–1147. [Google Scholar] [CrossRef]
  75. Gamonal, J.; Acevedo, A.; Bascones, A.; Jorge, O.; Silva, A. Characterization of cellular infiltrate, detection of chemokine receptor CCR5 and interleukin-8 and RANTES chemokines in adult periodontitis. J. Periodont. Res. 2001, 36, 194–203. [Google Scholar] [CrossRef]
  76. Yamazaki, K.; Nakajima, T.; Kubota, Y.; Gemmell, E.; Seymour, G.J.; Hara, K. Cytokine messenger RNA expression in chronic inflammatory periodontal disease. Oral Microbiol. Immunol. 1997, 12, 281–287. [Google Scholar] [CrossRef]
  77. Johnson, R.B.; Serio, F.G. The contribution of Interleukin-13 and -15 to the cytokine network within normal and diseased gingiva. J. Periodontol. 2007, 78, 691–695. [Google Scholar] [CrossRef]
  78. Ay, Z.Y.; Yilmaz, G.; Ozdem, M.; Kocak, H.; Sutcu, R.; Uskun, E.; Tonguc, M.O.; Kirzioglu, F. The gingival crevicular fluid levels of interleukin-11 and interleukin-17 in patients with aggressive periodontitis. J. Periodontol. 2012, 83, 1425–1431. [Google Scholar] [CrossRef] [PubMed]
  79. Yucel, O.O.; Berker, E.; Gariboglu, S.; Otlu, H. Interleukin-11, interleukin-1b, interleukin-12 and the pathogenesis of inflammatory periodontal diseases. J. Clin. Periodontol. 2008, 35, 365–370. [Google Scholar] [CrossRef] [PubMed]
  80. Prasad, R.; Suchetha, A.; Lakshmi, P.; Darshan, M.B.; Apoorva, S.M.; Ashit, G.B. Interleukin-11—Its role in the vicious cycle of inflammation, periodontitis and diabetes: A clinicobiochemical cross-sectional study. J. Indian Soc. Periodontol. 2015, 19, 159–163. [Google Scholar] [CrossRef]
  81. Tsai, I.S.; Tsai, C.C.; Ho, Y.P.; Ho, K.Y.; Wu, Y.M.; Hung, C.C. Interleukin-12 and interleukin-16 in periodontal disease. Cytokine 2005, 31, 34–40. [Google Scholar] [CrossRef]
  82. Nakajima, M.; Honda, T.; Miyauchi, S.; Yamazaki, K. Th2 cytokines efficiently stimulate periostin production in gingival fibroblasts but periostin does not induce an inflammatory response in gingival epithelial cells. Arch. Oral Biol. 2014, 59, 93–101. [Google Scholar] [CrossRef]
  83. Gundogar, H.; Ustun, K.; Senyurt, S.Z.; Ozdemir, E.C.; Sezer, U.; Erciyas, K. Gingival crevicular fluid levels of cytokine, chemokine and growth factors in patients with periodontitis or gingivitis and periodontally healthy subjects: A cross-sectional multiplex study. Cent. Eur. J. Immunol. 2021, 46, 474–480. [Google Scholar] [CrossRef]
  84. Vernal, R.; Dutzan, N.; Chaparro, A.; Puente, J.; Antonieta Valenzuela, M.; Gamonal, J. Levels of interleukin-17 in gingival crevicular fluid and in supernatants of cellular cultures of gingival tissue from patients with chronic periodontitis. J. Clin. Periodontol. 2005, 32, 383–389. [Google Scholar] [CrossRef]
  85. Takahashi, K.; Azuma, T.; Motohira, H.; Kinane, D.F.; Kitetsu, S. The potential role of interleukin-17 in the immunopathology of periodontal disease. J. Clin. Periodontol. 2005, 32, 369–374. [Google Scholar] [CrossRef] [PubMed]
  86. Schenkein, H.A.; Koertge, T.E.; Brooks, C.N.; Sabatini, R.; Purkall, D.E.; Tew, J.G. IL-17 in Sera from Patients with Aggressive Periodontitis. J. Dent. Res. 2010, 89, 943–947. [Google Scholar] [CrossRef] [PubMed]
  87. Xu, S.; Cao, X. Interleukin-17 and its expanding biological functions. Cell. Mol. Immunol. 2010, 7, 164–174. [Google Scholar] [CrossRef] [PubMed]
  88. Mitani, A.; Niedbala, W.; Fujimura, T.; Mogi, M.; Miyamae, S.; Higuchi, N.; Abe, A.; Hishikawa, T.; Mizutani, M.; Ishihara, Y.; et al. Increased Expression of Interleukin (IL)-35 and IL-17, But Not IL-27, in Gingival Tissues with Chronic Periodontitis. J. Periodontol. 2015, 86, 301–309. [Google Scholar] [CrossRef]
  89. Orozco, A.; Gemmell, E.; Bickel, M.; Seymour, G.J. Interleukin 18 and Periodontal Disease. J. Dent. Res. 2007, 86, 586–593. [Google Scholar] [CrossRef]
  90. Figueredo, C.M.; Rescala, B.; Teles, R.P.; Teles, F.P.; Fischer, R.G.; Haffajee, A.D.; Socransky, S.S.; Gustafsson, A. Increased interleukin-18 in gingival crevicular fluid from periodontitis patients. Oral Microbiol. Immunol. 2008, 23, 173–176. [Google Scholar] [CrossRef]
  91. Bostanci, N.; Emingil, G.; Saygan, B.; Turkoglu, O.; Atilla, G.; Curtis, M.A.; Belibasakis, G.N. Expression and regulation of the NALP3 inflammasome complex in periodontal diseases. Clin. Exp. Immunol. 2009, 157, 415–422. [Google Scholar] [CrossRef]
  92. Pradeep, A.R.; Daisy, H.; Hadge, P.; Garg, G.; Thorat, M. Correlation of Gingival Crevicular Fluid Interleukin-18 and Monocyte Chemoattractant Protein-1 Levels in Periodontal Health and Disease. J. Periodontol. 2009, 80, 1454–1461. [Google Scholar] [CrossRef]
  93. Dutzan, N.; Vernal, R.; Vaque, J.P.; Garcia-Sesnich, J.; Hernandez, M.; Abusleme, L.; Dezerega, A.; Gutkind, J.S.; Gamonal, J. Interleukin-21 expression and its association with proinflammatory cytokines in untreated chronic periodontitis patients. J. Periodontol. 2012, 83, 948–954. [Google Scholar] [CrossRef]
  94. Lin, P.; Jen, H.; Chiang, B.; Sheu, F.; Chuang, Y. Interleukin-21 suppresses the differentiation and functions of T helper 2 cells. Immunology 2014, 144, 668–676. [Google Scholar] [CrossRef]
  95. Selman, A.E.; Gorgulu, N.G.; DOĞAN, B. Salivary Levels of IL-21 as a Potential Marker of Stage III Grade C Periodontitis. Clin. Exp. Health Sci. 2021, 11, e989487. [Google Scholar] [CrossRef]
  96. Ohyama, H.; Kato-Kogoe, N.; Kuhara, A.; Nishimura, F.; Nakasho, K.; Yamanegi, K.; Yamada, N.; Hata, M.; Yamane, J.; Terada, N. The involvement of IL-23 and the Th17 pathway in periodontitis. J. Dent. Res. 2009, 88, 633–638. [Google Scholar] [CrossRef] [PubMed]
  97. Liukkonen, J.; Gursoy, U.K.; Pussinen, P.J.; Suominen, A.L.; Kononen, E. Salivary concentrations of Interleukin (IL)-1b, IL-17A, and IL-23 vary in relation to periodontal status. J. Periodontol. 2016, 87, 1484–1491. [Google Scholar] [CrossRef]
  98. Allam, J.P.; Duan, Y.; Heinemann, F.; Winter, J.; Gotz, W.; Deschner, J.; Wenghoefer, M.; Bieber, T.; Jepsen, S.; Novak, N. IL-23-producing CD68+ macrophage-like cells predominate within an IL-17-polarised infiltrate in chronic periodontitis lesions. J. Clin. Periodontol. 2011, 38, 879–886. [Google Scholar] [CrossRef] [PubMed]
  99. Baskar, K.; Gopalakarishnan, S.; Baskaran, S.; Alamelu, S.; Arumuganainar, D. Gingival crevicular fluid and salivary expression levels of IL-23 and IL-27 in periodontal health and disease. Int. J. Dent. Sci. 2025, 1, 432–441. [Google Scholar] [CrossRef]
  100. Ho, J.Y.; Yeo, B.S.; Yang, X.L.; Thirugnanam, T.; Hakeem, M.F.; Sahu, P.S.; Pulikkotil, S.J. Local and systemic expression profile of IL-10, IL-17, IL-27, IL-35 and IL-37 in periodontal diseases: A cross-sectional study. J. Contemp. Dent. Pract. 2021, 22, 73–79. [Google Scholar] [CrossRef]
  101. Köseoğlu, S.; Hatipoğlu, M.; Sağlam, M.; Enhoş, Ş.; Esen, H.H. Interleukin-33 could play an important role in the pathogenesis of periodontitis. J. Periodont. Res. 2014, 50, 525–534. [Google Scholar] [CrossRef] [PubMed]
  102. Lapérine, O.; Cloitre, A.; Caillon, J.; Huck, O.; Bugueno, I.M.; Pilet, P.; Sourice, S.; Tilly, E.L.; Palmer, G.; Jean-Luc Davideau, J.-L.; et al. Interleukin-33 and RANK-L Interplay in the Alveolar Bone Loss Associated to Periodontitis. PLoS ONE 2016, 11, e0168080. [Google Scholar] [CrossRef] [PubMed]
  103. Cayrol, C.; Girard, J.-P. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. Immunol. Rev. 2018, 281, 154–168. [Google Scholar] [CrossRef]
  104. Koseoglu, S.; Saglam, M.; Pekbagriyanik, T.; Savran, L.; Sutcu, R. Level of interleukin-35 in gingival crevicular fluid, saliva and plasma in periodontal disease and health. J. Periodontol. 2015, 86, 964–971. [Google Scholar] [CrossRef]
  105. Cloitre, A.; Halgand, B.; Sourice, S.; Caillon, J.; Huck, O.; Bugueno, I.M.; Batool, F.; Guicheux, J.; Geoffroy, V.; Lesclous, P. IL-36γ is a pivotal inflammatory player in periodontitis-associated bone loss. Sci. Rep. 2019, 9, 19257. [Google Scholar] [CrossRef]
  106. Heath, J.E.; Scholz, G.M.; Veith, P.D.; Reynolds, E.C. IL-36γ regulates mediators of tissue homeostasis in epithelial cells. Cytokine 2019, 119, 24–31. [Google Scholar] [CrossRef] [PubMed]
  107. Korkmaz, H.; Hatipoglu, M.; Kayar, N.A. Interleukin-38: A crucial player in periodontitis. Oral Dis. 2024, 30, 2523–2532. [Google Scholar] [CrossRef]
  108. Ali, I.H.; Salman, S.A. Potential of salivary IL-36γ, IL-38, and RANKL in differentiating periodontal health from periodontitis. Dentistry 3000 2025, 1, a001. [Google Scholar] [CrossRef]
  109. Bufler, P.; Azam, T.; Gamboni-Robertson, F.; Reznikov, L.L.; Kumar, S.; Dinarello, C.A.; Kim, S.-H. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc. Natl. Acad. Sci. USA 2002, 99, 13723–13728. [Google Scholar] [CrossRef]
  110. Offenbacher, S.; Jiao, Y.; Kim, S.J.; Marchesan, J.; Moss, K.L.; Jing, L.; Divaris, K.; Bencharit, S.; Agler, C.S.; Morelli, T.; et al. GWAS for Interleukin-1β levels in gingival crevicular fluid identifies IL37 variants in periodontal inflammation. Nat. Commun. 2018, 9, e3686. [Google Scholar] [CrossRef]
  111. Dutzan, N.; Gamonal, J.; Silva, A.; Sanz, M.; Vernal, R. Over-expression of forkhead box P3 and its association with receptor activator of nuclear factor–kappa B ligand, interleukin (IL)-17, IL-10 and transforming growth factor–beta during the progression of chronic periodontitis. J. Clin. Periodontol. 2009, 36, 396–403. [Google Scholar] [CrossRef]
  112. Khalaf, H.; Lonn, J.; Bengtsson, T. Cytokines and chemokines are differentially expressed in patients with periodontitis: Possible role for TGF-β1 as a marker for disease progression. Cytokine 2014, 67, 29–35. [Google Scholar] [CrossRef]
  113. Dutzan, N.; Vernal, R.; Hernandez, M.; Dezerega, A.; Rivera, O.; Silva, N.; Aguillon, J.C.; Puente, J.; Pozo, P.; Gamonal, J. Levels of interferon-gamma and transcription factor T-bet in progressive periodontal lesions in patients with chronic periodontitis. J. Periodontol. 2009, 80, 290–296. [Google Scholar] [CrossRef]
  114. Papathanasiou, E.; Teles, F.; Griffin, T.; Arguello, E.; Finkelman, M.; Hanley, J.; Theoharides, T.C. Gingival crevicular fluid levels of interferon-g, but not interleukin-4 or -33 or thymic stromal lymphopoietin, are increased in inflamed sites in patients with periodontal disease. J. Periodont. Res. 2014, 49, 55–61. [Google Scholar] [CrossRef]
  115. Isaza-Guzman, D.M.; Cardona-Velez, N.; Gaviria-Correa, D.E.; Martinez-Pabon, M.C.; Castano-Granada, M.C.; Tobin-Arroyave, S.I. Association study between salivary levels of interferon (IFN)-gamma, interleukin (IL)-17, IL-21, and IL-22 with chronic periodontitis. Arch. Oral Dis. 2015, 60, 91–99. [Google Scholar] [CrossRef]
  116. Booth, V.; Young, S.; Cruchley, A.; Taichman, N.S.; Paleolog, E. Vascular endothelial growth factor in human periodontal disease. J. Periodont. Res. 1998, 33, 491–499. [Google Scholar] [CrossRef]
  117. Kabashima, H.; Yoneda, M.; Nagata, K.; Hirofuji, T.; Maeda, K. The presence of chemokine (MCP-1, MIP-1alpha, MIP-1beta, IP-10, RANTES)-positive cells and chemokine receptor (CCR5, CXCR3)-positive cells in inflamed human gingival tissues. Cytokine 2002, 20, 70–77. [Google Scholar] [CrossRef] [PubMed]
  118. Gupta, M.; Chaturvedi, R.; Jain, A. Role of monocyte chemoattractant protein-1 (MCP-1) as an immune-diagnostic biomarker in the pathogenesis of chronic periodontal disease. Cytokine 2013, 61, 892–897. [Google Scholar] [CrossRef] [PubMed]
  119. Seymour, G.J.; Powell, R.N.; Aitken, J.F. Experimental gingivitis in humans: A clinical and histological investigation. J. Periodontol. 1983, 54, 522–528. [Google Scholar] [CrossRef]
  120. Seymour, G.J.; Gemmell, E.; Walsh, L.J.; Powell, R.N. Immunohistological analysis of experimental gingivitis in humans. Clin. Exp. Immunol. 1988, 71, 132–137. [Google Scholar] [PubMed] [PubMed Central]
  121. Berglundh, T.; Donati, M. Aspects of adaptive host response in periodontitis. J. Clin. Periodont. 2005, 32, 87–107. [Google Scholar] [CrossRef]
  122. Gaffen, S.L.; Hajishengallis, G. A new inflammatory cytokine on the block: Re-thinking periodontal disease and the Th1/Th2 paradigm in the context of Th17 cells and IL-17. J. Dent. Res. 2008, 87, 817–828. [Google Scholar] [CrossRef] [PubMed]
  123. Pan, W.; Wang, Q.; Chen, Q. The cytokine network involved in the host immune response to periodontitis. Int. J. Oral Sci. 2019, 11, 1–13. [Google Scholar] [CrossRef]
  124. Ohlrich, E.; Cullinan, M.; Seymour, G. The immunopathogenesis of periodontal disease. Aust. Dent. J. 2009, 54, S2–S10. [Google Scholar] [CrossRef]
  125. Okui, T.; Aoki, Y.; Ito, H.; Honda, T.; Yamazaki, K. The presence of IL-17+/FoxP3+ double-positive cells in periodontitis. J. Dent. Res. 2012, 91, 574–579. [Google Scholar] [CrossRef]
  126. Moutsopoulos, N.M.; Kling, H.M.; Angelov, N.; Jin, W.; Palmer, R.J.; Nares, S.; Osorio, M.; Wahl, S.M. Porphyromonas gingivalis promotes Th17 inducing pathways in chronic periodontitis. J. Autoimmun. 2012, 39, 294–303. [Google Scholar] [CrossRef]
  127. Dutzen, N.; Konkel, J.E.; Greenwell-Wild, T.; Moutsopoulos, N.M. Characterisation of the human immune cell network at the gingival barrier. Mucosal Immunol. 2016, 9, 1163–1172. [Google Scholar] [CrossRef]
  128. Gruber, R. Osteoimmunology: Inflammatory oseolysis and regeneration of the alveolar bone. J. Clin. Periodont. 2019, 46, 52–69. [Google Scholar] [CrossRef]
  129. Hajishengallis, G. Immune Evasion Strategies of Porphyromonas gingivalis. J. Oral Biosci. 2011, 53, 233–240. [Google Scholar] [CrossRef] [PubMed]
  130. Darveau, R.P.; Hajishengallis, G.; Curtis, M.A. Porphyromonas gingivalis as a potential community activist for disease. J. Dent. Res. 2012, 91, 816–820. [Google Scholar] [CrossRef] [PubMed]
  131. Widziolek, M.; Mieszkowska, A.; Marcinkowska, M.; Bartlomiej Salamaga Folkert, J.; Rakus, K.; Chadzinska, M.; Potempa, J.; Stafford, G.P.; Prajsnar, T.K.; Murdoch, C. Gingipains protect Porphyromonas gingivalis from macrophage-mediated phagocytic clearance. PLoS Pathog. 2025, 21, e1012821. [Google Scholar] [CrossRef] [PubMed]
  132. Zimny, A.; Płonczyńska, A.; Jakubowski, W.; Zubrzycka, N.; Potempa, J.; Sochalska, M. Porphyromonas gingivalis affects neutrophil pro-inflammatory activities. Front. Cell Dev. Biol. 2025, 13, e1419651, Erratum in Front. Cell Dev. Biol. 2025, 13, 1652545. https://doi.org/10.3389/fcell.2025.1652545. [Google Scholar] [CrossRef] [PubMed]
  133. Abdi, K.; Chen, T.; Klein, B.A.; Tai, A.K.; Coursen, J.; Liu, X.; Skinner, J.; Periasamy, S.; Choi, Y.; Kessler, B.M.; et al. Mechanisms by which Porphyromonas gingivalis evades innate immunity. PLoS ONE 2017, 12, e0182164. [Google Scholar] [CrossRef]
  134. Zou, Z.; Fang, J.; Ma, W.; Guo, J.; Shan, Z.; Ma, D.; Hu, Q.; Wen, L.; Wang, Z. Porphyromonas gingivalis Gingipains Destroy the Vascular Barrier and Reduce CD99 and CD99L2 Expression to Regulate Transendothelial Migration. Microbiol. Spectrum 2023, 11, e04769-22. [Google Scholar] [CrossRef] [PubMed]
  135. Angabo, S.; Karthikeyan Pandi David, K.; Steinmetz, O.; Hasnaa Makkawi Farhat, M.; Eli-Berchoer, L.; Nadeem Darawshi Kawasaki, H.; Nussbaum, G. CD47 and thrombospondin-1 contribute to immune evasion by Porphyromonas gingivalis. Proc. Natl. Acad. Sci. USA 2024, 121, e2405534121. [Google Scholar] [CrossRef]
  136. Liu, X.; Jin, J.; Liu, Y.; Shen, Z.; Zhao, R.; Ou, L.; Xing, T. Targeting TSP-1 decreased periodontitis by attenuating extracellular matrix degradation and alveolar bone destruction. Int. Immunopharmacol. 2021, 96, e107618. [Google Scholar] [CrossRef]
  137. Slocum, C.; Coats, S.R.; Hua, N.; Kramer, C.; Papadopoulos, G.; Weinberg, E.O.; Gudino, C.V.; Hamilton, J.A.; Darveau, R.P.; Genco, C.A. Distinct Lipid A Moieties Contribute to Pathogen-Induced Site-Specific Vascular Inflammation. PLoS Pathogens 2014, 10, e1004215. [Google Scholar] [CrossRef]
  138. Olsen, I.; Singhrao, S.K. Importance of heterogeneity in Porhyromonas gingivalis lipopolysaccharide lipid A in tissue specific inflammatory signalling. J. Oral Microbiol. 2018, 10, e1440128. [Google Scholar] [CrossRef]
  139. Domae, E.; Mori, T.; Hanaoka, M. Recognition of Porphyromonas gingivalis lipopolysaccharide by human caspase−4 depends on lipopolysaccharide purity and guanylate-binding protein 1. J. Oral Microbiol. 2025, 17, e2589652. [Google Scholar] [CrossRef]
  140. Holden, J.A.; Attard, T.J.; Laughton, K.M.; Mansell, A.; O’Brien-Simpson, N.M.; Reynolds, E.C. Porphyromonas gingivalis lipopolysaccharide weakly activates M1 and M2 polarised mouse macrophages but induces inflammatory cytokines. Infect. Immun. 2014, 82, 4190–4203. [Google Scholar] [CrossRef]
  141. Duncan, L.; Yoshioka, M.; Chandad, F.; Grenier, D. Loss of lipopolysaccharide receptor CD14 from the surface of human macrophage-like cells mediated by Porphyromonas gingivalis outer membrane vesicles. Microb. Pathogen 2004, 36, 319–325. [Google Scholar] [CrossRef]
  142. Coats, S.R.; Su, T.H.; Luderman Miller, Z.; King, A.J.; Ortiz, J.; Reddy, A.; Alaei, S.R.; Jain, S. Porphyromonas gingivalis outer membrane vesicles divert host innate immunity and promote inflammation via C4′ monophosphorylated lipid A. J. Immunol. 2025, 214, 1008–1021. [Google Scholar] [CrossRef]
  143. Foey, A.D.; Crean, S.-J. Macrophage subset sensitivity to endotoxin tolerization by Porphyromonas gingivalis. PLoS ONE 2013, 8, e67955. [Google Scholar] [CrossRef] [PubMed][Green Version]
  144. Al-Shaghdali, K.; Durante, B.; Hayward, C.; Beal, J.; Foey, A. Macrophage subsets exhibit distinct E. coli-LPS tolerisable cytokines associated with the negative regulators, IRAK-M and Tollip. PLoS ONE 2019, 14, e0214681. [Google Scholar] [CrossRef] [PubMed]
  145. Olsen, I.; Taubman, M.A.; Singhrao, S.K. Porphyromonas gingivalis suppresses adaptive immunity in periodontitis, atherosclerosis, and Alzheimer’s disease. J. Oral Microbiol. 2016, 8, 33029. [Google Scholar] [CrossRef]
  146. Mahanonda, R.; Sa-Ard-Lam, N.; Montreekachon, P.; Pimkhaokham, A.; Yongvanichit, K.; Fukuda, M.M.; Pichyangkul, S. IL-8 and IDO expression by human gingival fibroblasts via TLRs. J. Immunol. 2007, 178, 1151–1157. [Google Scholar] [CrossRef] [PubMed]
  147. Zheng, Y.; Wang, Z.; Weng, Y.; Sitosari, H.; He, Y.; Zhang, X.; Shiotsu, N.; Fukuhara, Y.; Ikegame, M.; Okamura, H. Gingipain regulates isoform switches of PD-L1 in macrophages infected with Porphyromonas gingivalis. Sci. Rep. 2025, 15, e10462. [Google Scholar] [CrossRef] [PubMed]
  148. Cobb, C.M. Clinical significance of non-surgical periodontal therapy: An evidence-based perspective of scaling and root planing. J. Clin. Periodontol. 2002, 29, 6–16. [Google Scholar] [CrossRef]
  149. (AAP) American Academy of Periodontology. Comprehensive periodontal therapy: Astatement by the American Academy of Periodontology. J. Periodontol. 2011, 82, 943–949. [Google Scholar] [CrossRef]
  150. Lindhe, J.; Lang, N.P.; Karring, T. Clinical Periodontology and Implant Dentistry, 6th ed.; Wiley-Blackwell: Oxford, UK, 2015; ISBN 978-1-118-94047-1. [Google Scholar]
  151. Hamblin, M.R. Antimicrobial photodynamic inactivation: A bright new technique to kill resistant microbes. Curr. Opin. Microbiol. 2016, 33, 67–73. [Google Scholar] [CrossRef]
  152. Sculean, A.; Alessandri, R.; Miron, R.; Saliv, G.E.; Bosshardt, D.D. Enamel matrix proteins and periodontal wound healing and regeneration. Clin. Adv. Periodontics 2011, 2, 101–117. [Google Scholar] [CrossRef]
  153. Liang, S.; Krauss, J.L.; Domon, H.; McIntosh, M.L.; Hosur, K.B.; Qu, H.; Li, F.; Tzekou, A.; Lambris, J.D.; Hajishengallis, G. The C5a Receptor Impairs IL-12–Dependent Clearance of Porphyromonas gingivalis and Is Required for Induction of Periodontal Bone Loss. J. Immunol. 2010, 186, 869–877. [Google Scholar] [CrossRef]
  154. Han, J.; Meade, J.; Devine, D.; Sadeghpour, A.; Rappolt, M.; Goycoolea, F.M. Chitosan-coated liposomal systems for delivery of antibacterial peptide LL17-32 to Porphyromonas gingivalis. Heliyon 2024, 10, e34554. [Google Scholar] [CrossRef] [PubMed]
  155. Fletcher, J.; Nair, S.; Poole, S.; Henderson, B.; Wilson, M. Cytokine degradation by biofilms of Porphyromonas gingivalis. Curr. Microbiol. 1998, 36, 216–219. [Google Scholar] [CrossRef] [PubMed]
  156. Nakao, R.; Hasegawa, H.; Dongying, B.; Ohnishi, M.; Senpuku, H. Assessment of outer membrane vesicles of periodontopathic bacterium Porphyromonas gingivalis as possible mucosal immunogen. Vaccine 2016, 34, 4626–4634. [Google Scholar] [CrossRef] [PubMed]
Microorganisms 14 00641 g001
Figure 1. The inter-relationship of P. gingivalis, microbiome, immunity and immune evasion determines PD. The balance between healthy gingival and periodontal tissue homeostasis of the oral microbiome and dysbiosis associated with PD progression and chronicity is represented by the predominance of Gram-positive cocci in the tolerogenic/anti-inflammatory environment in the green triangle at the bottom of the figure and its progression to Gram-negative rods and spirochaetes in the red triangle. The changes in the microbiome influence, and are influenced by, the immune state indicated as tolerization/suppression (Toln) in the green boxes and activation (red boxes) at the top of the figure. This bi-directional relationship between immune activation status and microbiome status is indicated by green or red arrows to the sides of the figure; such an inter-relationship is linked to the stages of immune progression resulting in episodes of relapse and remission—inflammation/anti-pathogen response vs. anti-inflammatory/suppression of anti-pathogen response (cellular/molecular mechanisms indicated in central panel of gingival/periodontal tissues). The mechanisms associated with PD progression are indicated numerically and are as follows: 1. Homeostatic/healthy tissue is associated with the oral microbiome, M2 anti-inflammatory Mϕs, DC/APC interaction with and immune toln by Tregs. 2. Early actn by plaque build-up and microbial changes result in M1 Mϕ and Nϕ (PMN) infiltration and actn, associated with gingivitis. 3. Early ET may suppress M1 pro-inflammatory actn, favouring microbial replication, hence dysbiosis towards P. gingivalis and red complex bacteria. 4. Changes to oral microbiome favour further M1 actn and pro-inflammatory cytokine production, driving tissue-destructive, pathogen-clearing Th1-dependent CMI. 5. In an attempt to control this CMI, toln may be initiated by PG-LPS, resulting in Treg recruitment, whereas M1 Mϕs are refractory to ET and may exhibit plasticity: changing to an M2 subset. 6. FoxP3+ IL-17+ Tregs polarize towards Th17 cells, where IL-17 prodn perpetuates inflammation by the actn of Nϕs and Mϕs. 7. Th17-driven pathology may persist, but Mϕ responses to PL-LPS result in M1 to M2 polarization, driving both tolerogenic mechanisms and immune activation by Th2-mediated B cell humoral responses. 8. Immune cells and the cycling of actn/Toln by the inflammatory process and progression to PD further alter the oral microbiome (8a) and immune inflammatory mediators (antibodies, cytokines, ROS and MMPs) (8b).
Figure 1. The inter-relationship of P. gingivalis, microbiome, immunity and immune evasion determines PD. The balance between healthy gingival and periodontal tissue homeostasis of the oral microbiome and dysbiosis associated with PD progression and chronicity is represented by the predominance of Gram-positive cocci in the tolerogenic/anti-inflammatory environment in the green triangle at the bottom of the figure and its progression to Gram-negative rods and spirochaetes in the red triangle. The changes in the microbiome influence, and are influenced by, the immune state indicated as tolerization/suppression (Toln) in the green boxes and activation (red boxes) at the top of the figure. This bi-directional relationship between immune activation status and microbiome status is indicated by green or red arrows to the sides of the figure; such an inter-relationship is linked to the stages of immune progression resulting in episodes of relapse and remission—inflammation/anti-pathogen response vs. anti-inflammatory/suppression of anti-pathogen response (cellular/molecular mechanisms indicated in central panel of gingival/periodontal tissues). The mechanisms associated with PD progression are indicated numerically and are as follows: 1. Homeostatic/healthy tissue is associated with the oral microbiome, M2 anti-inflammatory Mϕs, DC/APC interaction with and immune toln by Tregs. 2. Early actn by plaque build-up and microbial changes result in M1 Mϕ and Nϕ (PMN) infiltration and actn, associated with gingivitis. 3. Early ET may suppress M1 pro-inflammatory actn, favouring microbial replication, hence dysbiosis towards P. gingivalis and red complex bacteria. 4. Changes to oral microbiome favour further M1 actn and pro-inflammatory cytokine production, driving tissue-destructive, pathogen-clearing Th1-dependent CMI. 5. In an attempt to control this CMI, toln may be initiated by PG-LPS, resulting in Treg recruitment, whereas M1 Mϕs are refractory to ET and may exhibit plasticity: changing to an M2 subset. 6. FoxP3+ IL-17+ Tregs polarize towards Th17 cells, where IL-17 prodn perpetuates inflammation by the actn of Nϕs and Mϕs. 7. Th17-driven pathology may persist, but Mϕ responses to PL-LPS result in M1 to M2 polarization, driving both tolerogenic mechanisms and immune activation by Th2-mediated B cell humoral responses. 8. Immune cells and the cycling of actn/Toln by the inflammatory process and progression to PD further alter the oral microbiome (8a) and immune inflammatory mediators (antibodies, cytokines, ROS and MMPs) (8b).
Microorganisms 14 00641 g001
Table 1. Cytokine profiles in periodontal disease.
Table 1. Cytokine profiles in periodontal disease.
CytokineSampleRole in PD/NotesPD Ref
TNFαGCF, serum, perio tissue,
PD-Mϕs		Bone resorpn, synergy with IL-1. Acute phase, prevents repair.[57,58,59]
IL-1αGCF, perio tissue, PD-Mϕs,
gingival fibroblasts		Alarmin. Protease synthesis.[58,60,61]
IL-1βGCF, perio tissue, PD-Mϕs,
saliva, serum		IL-1β+ Mϕs elevated in PD. MMP prodn. Bone resorpn.[58,62,63,64,65]
IL-1RaGCF, perio tissueUp- and down-regulated in PD. Antagonize pro-inflammatory effect of IL-1. Limit bone resorpn.[66,67,68]
IL-4GCFPD—low, elevated in remission. M2 and Th2 polarization.[59,66,69,70]
IL-6GCF, perio tissue and plasma, PD-MϕsPD—elevated. B cell actn and Ig prodn. Periodontal damage and bone loss. OC Diffn.[58,69,71,72]
IL-8GCF, perio tissue, PD-MϕsNeutrophil migration to gingival sulcus. NET formation.[58,73,74,75]
IL-10Perio tissueCD8+ T prodn of IL-10. Anti-inflamm. M2/Treg polarization. Induces TIMPs, inhibits MMPs. Sometimes suppd.[64,76,77]
IL-11GCF, perio tissueDecreased IL-11. Anti-inflamm.[78,79,80]
IL-12Perio tissuePD: IL-12+ B cells elevated. Th1 diffn
NK actn. Synergizes with IL-18.		[64,76,81]
IL-13PD perio tissueInductn of periostin and Th2-mediated tissue destruction in periodontium.[77,82]
IL-15Perio tissueIL15: decr. In PD. Incr. iNOS/NO in gingival epithelial cells. Synergizes with RANKL in osteoclastogenesis.[69,77,83]
IL17GCF, sera, perio tissueElevated in PD. NK actn. Mϕ actn. Nϕ actn. IL-17 prodn by Th17 and Nϕs.[78,84,85,86,87,88]
IL-18GCF, saliva, serumPD: NK actn, Nϕ actn and Th1: IFNγ prodn. Synergy with IL-12. IL-18 actn by NLRP3.[65,89,90,91,92]
IL-21SalivaStage III Grade C periodontitis: pro-inflamm, released by Th17 cells, suppn Th2-IL-13. IL-21 elevated in saliva.[93,94,95]
IL-23Perio tissue, GCF, saliva,
PD Mϕs		Th17 diffn.[96,97,98,99]
IL-27Perio tissue, GCF, salivaIL-27 decreased—anti-inflammatory: suppn of IL-17.[88,99,100]
IL-33Perio tissue, GCFPD:Alarmin, ILC2, Treg, Th2 CK and NK Actn, osteoclastogenesis and RANKL—alveolar bone loss, microbial dysbiosis.[101,102,103]
IL-35GCF, perio tissuePD/CP. Immune tolerance. Diffn and functionality of iTreg35 cells.[88,104]
IL-36PD perio tissue, GCF, salivaDC, Mϕ and Nϕ chemotaxis, amplifn of IL-17 secretion. Stimn Th17 chemokines and bone resorpn.[105,106,107,108]
IL-36RaPD perio tissueAnti-inflamm. Antagonistic to IL-36 functionality. Down-regulated expression.[105]
IL-37Perio tissuePD: anti-inflamm. Smad-3 binding: TGFβ activity. Suppresses innate and adaptive IRs. Inhibitor of IL-18.[109,110]
IL-38PD GCF, salivaBlocks pro-inflammatory cytokines. Down-regulated expression in PD.[107,108]
TGFβPerio tissue, GCF, saliva,
serum		Anti-inflamm. Inhibits MMP synthesis. Stimn of GF repair activity. Sometimes suppressed in PD.[111,112]
IFNγPerio tissue, GCF, salivaM1 polarization, DTH response, Th2 suppression. NK function. Inductn of MHC and adhesion molecules.[77,113,114,115]
MCP-1
IP-10
VEGF		PD: GCFMonocyte and T-cell chemotaxis.
Inductn of angiogenesis; pro-inflamm.		[83,116,117,118]
Cytokine expression and/or protein production associated with PD, aggressive PD (APD) and chronic periodontitis (CP). Cytokines indicated were detected as mRNA transcripts or proteins produced and measured by immunohistochemistry staining in periodontal tissue (perio tissue) or secreted protein measured by ELISA from periodontal disease macrophages (PD-Mϕs) or in serum, saliva or gingival crevicular fluid (GCF). In addition, functional roles played by these cytokines in PD immunopathology are indicated. Cytokines indicated: IL—interleukin; TNFα—tumour necrosis factor-alpha; TGFβ—transforming growth factor-beta; IL-1/36Ra—IL-1 and IL-36 receptor antagonist; IFNγ—interferon-gamma. Abbreviations: resorpn, resorption; prodn, production; actn, activation; diffn, differentiation; inflamm. inflammatory; suppd, suppressed; suppn, suppression; inductn, induction; stimn, stimulation; amplifn, amplification; incr., increase; decr., decrease; NET, neutrophil extracellular trap; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinases; NK, natural killer cell; GFs, gingival fibroblasts; IR, immune response. Cytokines labelled in green denote anti-inflammatory/regulatory cytokines. Cytokines indicated in black are pro-inflammatory and activatory.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Robins, S.; Strachan, A.; Salih, V.; Foey, A. Periodontal Disease and Its Association with Porphyromonas gingivalis: Current Understanding of Microbial Dysbiosis, Immunopathology and Immune Evasion. Microorganisms 2026, 14, 641. https://doi.org/10.3390/microorganisms14030641

AMA Style

Robins S, Strachan A, Salih V, Foey A. Periodontal Disease and Its Association with Porphyromonas gingivalis: Current Understanding of Microbial Dysbiosis, Immunopathology and Immune Evasion. Microorganisms. 2026; 14(3):641. https://doi.org/10.3390/microorganisms14030641

Chicago/Turabian Style

Robins, Samantha, Alex Strachan, Vehid Salih, and Andrew Foey. 2026. "Periodontal Disease and Its Association with Porphyromonas gingivalis: Current Understanding of Microbial Dysbiosis, Immunopathology and Immune Evasion" Microorganisms 14, no. 3: 641. https://doi.org/10.3390/microorganisms14030641

APA Style

Robins, S., Strachan, A., Salih, V., & Foey, A. (2026). Periodontal Disease and Its Association with Porphyromonas gingivalis: Current Understanding of Microbial Dysbiosis, Immunopathology and Immune Evasion. Microorganisms, 14(3), 641. https://doi.org/10.3390/microorganisms14030641

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop